The mechanism by which the wild-type KRAS allele imparts a growth inhibitory effect to
oncogenic KRAS in various cancers, including lung adenocarcinoma (LUAD), is poorly …

Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver
events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly …

Mutational activation of KRAS is a common oncogenic event in lung cancer and other
epithelial cancer types. Efforts to develop therapies that counteract the oncogenic effects of …

Background Lung cancer patients with KRAS mutation (s) have a poor prognosis due in part
to the development of resistance to currently available therapeutic interventions …

KRAS is the most frequently mutated oncogene in cancer and KRAS mutation is commonly
associated with poor prognosis and resistance to therapy. Since the KRAS oncoprotein is …

Simple Summary Since the Kirsten rat sarcoma viral oncogene homolog (KRAS) is mutated
in about 25% of all human cancers and is at the center of pathways involved in …

Simple Summary KRAS is one of the oncogenic proteins and best well-known GTPase
proteins. Although KRAS serves as regulation of cellular process, abnormal mutated and …

BACKGROUND The KRAS proto-oncogene is among the most frequently mutated genes in
cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric …

Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic
subtype of non–small cell lung cancer (NSCLC), and is an important target for drug …

Assembly of RAS molecules into complexes at the cell membrane is critical for RAS
signaling. We previously showed that oncogenic KRAS codon 61 mutations increase its …